MCID: SQM006
MIFTS: 59

Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 76 53 37 29 6 15 73
Carcinoma, Squamous Cell 76 53 44
Epidermoid Carcinoma 12 76 53
Squamous Cell Cancer 12 55 15
Squamous Cell Carcinoma of the Skin 29 6
Squamous Cell Carcinoma - Category 73
Malignant Squamous Cell Neoplasm 73
Squamous Cell Carcinoma of Skin 73
Malignant Squamous Cell Tumor 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 53
Neoplasms, Squamous Cell 44
Carcinoma Squamous Cell 55
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
NCIt 50 C2929
SNOMED-CT 68 28899001
KEGG 37 H00040

Summaries for Squamous Cell Carcinoma

NIH Rare Diseases : 53 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable.

MalaCards based summary : Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and tongue squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Glioblastoma Multiforme and Senescence and Autophagy in Cancer. The drugs Erbitux and Intron A have been mentioned in the context of this disorder. Affiliated tissues include lung, tongue and skin.

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

Wikipedia : 76 Squamous cell carcinomas (SCCs), also known as epidermoid carcinoma, comprise a number of different... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 967)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 34.6 BRAF C5orf66-AS1 H19 HOTAIR HRAS MIR205
2 tongue squamous cell carcinoma 34.3 LINC01503 MALAT1 TP53 UCA1
3 oral squamous cell carcinoma 34.3 CCAT2 H19 HOTAIR MALAT1 TUG1 UCA1
4 laryngeal squamous cell carcinoma 34.2 H19 HOTAIR MALAT1 TP53
5 vulva squamous cell carcinoma 34.1 MALAT1 TP53
6 lung squamous cell carcinoma 34.1 BRAF CCAT2 HRAS SOX2-OT TP53 TUG1
7 esophagus squamous cell carcinoma 34.1 HOTAIR LINC01233
8 esophageal cancer 33.7 C5orf66-AS1 CASC9 H19 HOTAIR HRAS MALAT1
9 nasopharyngeal carcinoma 33.3 CASC9 H19 HOTAIR HRAS MALAT1 TP53
10 adenocarcinoma 33.0 BRAF H19 HRAS MALAT1 TP53
11 lung cancer 32.3 BRAF CASC9 CCAT2 DDR2 H19 HOTAIR
12 prostate cancer 32.2 CCAT2 H19 HOTAIR HRAS MALAT1 MIR205
13 bladder cancer 32.1 C5orf66-AS1 CCAT2 H19 HOTAIR HRAS MALAT1
14 lung cancer susceptibility 3 31.2 BRAF H19 HOTAIR HRAS MALAT1 TP53
15 melanoma 31.1 BRAF H19 HOTAIR MALAT1 MIR205 SOX2-OT
16 gastric adenocarcinoma 31.0 BRAF H19 HOTAIR HRAS TP53
17 small cell cancer of the lung 30.9 CCAT2 HOTAIR MALAT1 TP53 TUG1
18 cervical cancer 30.9 CCAT2 H19 HOTAIR HRAS MALAT1 SPRY4-IT1
19 leukemia, chronic lymphocytic 2 30.9 BRAF HRAS TP53
20 thyroid cancer, nonmedullary, 1 30.9 BRAF H19 HOTAIR MALAT1
21 transitional cell carcinoma 30.8 BRAF HRAS TP53
22 gastric cardia adenocarcinoma 30.7 C5orf66-AS1 H19 HOTAIR
23 thyroid cancer 30.6 BRAF H19 HOTAIR HRAS MALAT1 TP53
24 suppression of tumorigenicity 12 30.5 BRAF HRAS TP53
25 mature teratoma 30.5 BRAF TP53
26 colorectal adenocarcinoma 30.5 BRAF HRAS TP53
27 hepatocellular carcinoma 30.3 CCAT2 H19 HOTAIR HRAS MALAT1 MIR205
28 intrahepatic cholangiocarcinoma 30.3 CCAT2 TP53 TUG1
29 b-cell lymphomas 30.2 HOTAIR MALAT1 TP53 TUG1
30 leukemia, chronic myeloid 30.2 H19 HOTAIR HRAS UCA1
31 breast cancer 30.2 BRAF CCAT2 H19 HOTAIR HRAS MALAT1
32 gastric cancer 30.1 CASC9 CCAT2 H19 HOTAIR MALAT1 RIOX2
33 renal cell carcinoma, nonpapillary 30.1 H19 HOTAIR MALAT1 TUG1 UCA1
34 bladder urothelial carcinoma 30.1 BRAF HOTAIR HRAS MALAT1 TP53 TUG1
35 cholangiocarcinoma 30.0 BRAF CCAT2 H19 MALAT1 SOX2-OT SPRY4-IT1
36 glioma 30.0 BRAF CCAT2 H19 HOTAIR MALAT1 SPRY4-IT1
37 colorectal cancer 29.9 BRAF CCAT2 H19 HOTAIR HRAS MALAT1
38 osteogenic sarcoma 29.9 CCAT2 H19 HOTAIR MALAT1 SOX2-OT TP53
39 myeloma, multiple 29.9 BRAF H19 HOTAIR HRAS MALAT1 TP53
40 adamantinoma of long bones 29.6 BRAF CCAT2 H19 HOTAIR MALAT1 SOX2-OT
41 gastric squamous cell carcinoma 12.6
42 rectum squamous cell carcinoma 12.6
43 basaloid squamous cell carcinoma 12.6
44 conjunctival squamous cell carcinoma 12.6
45 colon squamous cell carcinoma 12.6
46 prostate squamous cell carcinoma 12.6
47 adenoid squamous cell carcinoma 12.6
48 gallbladder squamous cell carcinoma 12.6
49 keratinizing squamous cell carcinoma 12.5
50 renal pelvis squamous cell carcinoma 12.5

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

Drugs & Therapeutics for Squamous Cell Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 603)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 114977-28-5 148124
3
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
5
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
6
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
7
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
8
Titanium dioxide Approved Phase 4 13463-67-7
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
11
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
12
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 6006 143
13
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 184475-35-2 123631
14
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 41575-94-4 10339178 38904 498142
15
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
16
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 95734-82-0
17
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
18
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
19
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
20
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2 112887-68-0 104758
21
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
22
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
23
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
24
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
25
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
26
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 62-33-9, 60-00-4 6049
27
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
28
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
30
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
31
Acitretin Approved Phase 4,Phase 2,Not Applicable 55079-83-9 5284513 6437841
32
Azathioprine Approved Phase 4 446-86-6 2265
33
Mycophenolic acid Approved Phase 4 24280-93-1 446541
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
35
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
36
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
37 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Endostatins Phase 4,Phase 3,Phase 2,Phase 1 71581480
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Anti-Allergic Agents Phase 4,Phase 2
50 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2256)
# Name Status NCT ID Phase Drugs
1 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
2 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
5 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
6 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Unknown status NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
7 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
8 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
9 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
10 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
11 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
12 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
13 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
14 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
15 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
16 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
17 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
18 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
19 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
20 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
21 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
22 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
23 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
24 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
25 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
26 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
27 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
28 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Not yet recruiting NCT03388931 Phase 4
29 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
30 Apatinib for Advanced Lung Squmamous Carcinoma Not yet recruiting NCT03725423 Phase 4 Apatinib
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
32 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
33 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
34 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
35 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
36 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
37 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
38 Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Unknown status NCT02485548 Phase 3 Raltitrexed;5-fluorouracil;Cisplatin
39 Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
40 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
41 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
42 Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
43 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
44 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
45 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
46 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
47 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
48 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
49 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
50 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 29
2 Squamous Cell Carcinoma of the Skin 29

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

41
Lung, Tongue, Skin, Lymph Node, Cervix, Endothelial, T Cells

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 16142)
# Title Authors Year
1
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
2
Squamous cell carcinoma arising in a partially ruptured giant mature cystic teratoma: A case report. ( 30386447 )
2019
3
Slowly progressive facial paralysis: Intraneural squamous cell carcinoma of unknown primary. ( 30472126 )
2019
4
To investigate the affiliation of XRCC-1 Gene Arg194Trp polymorphism in alcohol and tobacco substance users and loco-regionally progressed Laryngeal squamous cell carcinoma. ( 30370213 )
2019
5
Suicide Gene Therapy for Oral Squamous Cell Carcinoma. ( 30539528 )
2019
6
Suicide Gene Therapy of Oral Squamous Cell Carcinoma and Cervical Carcinoma In Vitro. ( 30539538 )
2019
7
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-κB pathway. ( 30551455 )
2019
8
Licochalcone H induces the apoptosis of human oral squamous cell carcinoma cells via regulation of matrin 3. ( 30320347 )
2019
9
Asymmetrical proliferative pattern loss linked to cyclin D1 overexpression in adjacent non-tumour epithelium in oral squamous cell carcinoma. ( 30321764 )
2019
10
Management of the Neck in Oral Squamous Cell Carcinoma: Background, Classification, and Current Philosophy. ( 30449527 )
2019
11
Licochalcone D directly targets JAK2 to induced apoptosis in human oral squamous cell carcinoma. ( 30070696 )
2019
12
Estimation of salivary and serum basic fibroblast growth factor in treated and untreated patients with oral squamous cell carcinoma. ( 30197859 )
2019
13
Analysis of stromal mucin in oral epithelial dysplasia & oral squamous cell carcinoma- A histochemical study. ( 30210999 )
2019
14
Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. ( 30510992 )
2019
15
Phospho-Sphingosine Kinase 1 Expression in Lymphatic Spread of Esophageal Squamous Cell Carcinoma. ( 30527463 )
2019
16
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. ( 30546955 )
2019
17
SRPX2 knockdown inhibits cell proliferation and metastasis and promotes chemosensitivity in esophageal squamous cell carcinoma. ( 30551519 )
2019
18
MicroRNA-384 inhibits the progression of esophageal squamous cell carcinoma through blockade of the LIMK1/cofilin signaling pathway by binding to LIMK1. ( 30551528 )
2019
19
Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma. ( 30431077 )
2019
20
Dysregulated circRNAs and ceRNA network in esophageal squamous cell carcinoma. ( 30468655 )
2019
21
Poorly differentiated plasmacytoid squamous cell carcinoma: Case report of a rare malignancy. ( 30472136 )
2019
22
Cutaneous Squamous Cell Carcinoma. ( 30497667 )
2019
23
High expression of TMEM40 contributes to progressive features of tongue squamous cell carcinoma. ( 30320346 )
2019
24
Detection of high-grade dysplasia, carcinoma in situ and squamous cell carcinoma in the upper aerodigestive tract: Recommendations for optimal use and interpretation of narrow-band imaging. ( 30222908 )
2019
25
CRNDE promotes cell tongue squamous cell carcinoma cell growth and invasion through suppressing miR-384. ( 30242873 )
2019
26
PADI4 stimulates esophageal squamous cell carcinoma tumor growth and up-regulates CA9 expression. ( 30242913 )
2019
27
Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis. ( 30182448 )
2019
28
The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. ( 30070689 )
2019
29
XBP1 promotes tumor invasion and is associated with poor prognosis in oral squamous cell carcinoma. ( 29916547 )
2018
30
Curcumin enhances anti-tumor immune response in tongue squamous cell carcinoma. ( 29751146 )
2018
31
Squamous Cell Carcinoma of the Gingiva Mimicking Periodontal Disease: A Diagnostic Challenge and Therapeutic Dilemma. ( 29447319 )
2018
32
The Positive Relationship Between I^H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. ( 29275316 )
2018
33
Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma. ( 29977357 )
2018
34
Airway brushing as a new experimental methodology to detect airway gene expression signatures in mouse lung squamous cell carcinoma. ( 29891994 )
2018
35
Serum bilirubin level predicts post-operative overall survival in oral squamous cell carcinoma. ( 29430757 )
2018
36
CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. ( 29360827 )
2018
37
NIPA-like domain containing 1 is a novel tumor-promoting factor in oral squamous cell carcinoma. ( 29464350 )
2018
38
FNDC3B promotes epithelial-mesenchymal transition in tongue squamous cell carcinoma cells in a hypoxic microenvironment. ( 29393475 )
2018
39
Reply to 'Comment on 'Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis". ( 29449674 )
2018
40
Association of Retinoic Acid Receptor I^ Gene With Onset and Progression of Lichen Sclerosus-Associated Vulvar Squamous Cell Carcinoma. ( 29898214 )
2018
41
Degenerated Keratinized Tumor Cells in Oropharyngeal Human Papilloma Virus-Associated Squamous Cell Carcinoma: A Pitfall in p16 Immunostaining of Fine-Needle Aspiration Specimens. ( 29966127 )
2018
42
Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. ( 29748009 )
2018
43
TGF-I^1/TI^RII/Smad3 signaling pathway promotes VEGF expression in oral squamous cell carcinoma tumor-associated macrophages. ( 29462614 )
2018
44
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. ( 29920955 )
2018
45
Expression of Sphingosine Kinase-1 Is Associated with Invasiveness and Poor Prognosis of Oral Squamous Cell Carcinoma. ( 29491060 )
2018
46
Non-invasive imaging of actinic cheilitis and squamous cell carcinoma of the lip. ( 29725529 )
2018
47
Canonical Wnt pathway gene expression and their clinical correlation in oral squamous cell carcinoma. ( 29900911 )
2018
48
Expression of CD44, CD44v9, ABCG2, CD24, Bmi-1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors. ( 29963189 )
2018
49
The long non-coding RNA AK001796 contributes to tumor growth via regulating expression of p53 in esophageal squamous cell carcinoma. ( 29568233 )
2018
50
Gadd45a gene silencing by RNAi promotes cell proliferation and inhibits apoptosis and senescence in skin squamous cell carcinoma through the p53 signaling pathway. ( 29663367 )
2018

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6 (show top 50) (show all 222)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
5 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
6 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
10 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
11 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
12 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
13 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
15 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
17 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
19 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
20 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
21 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
22 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
23 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
24 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
25 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
26 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
27 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
28 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
29 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
30 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
31 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh37 Chromosome 6, 31940123: 31940123
32 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 GRCh38 Chromosome 6, 31972346: 31972346
33 STK19 NM_004197.1(STK19): c.265G> A (p.Asp89Asn) single nucleotide variant Likely pathogenic rs267600971 NCBI36 Chromosome 6, 32048102: 32048102
34 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh37 Chromosome 9, 21971017: 21971017
35 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 GRCh38 Chromosome 9, 21971018: 21971018
36 CDKN2A NM_000077.4(CDKN2A): c.341C> T (p.Pro114Leu) single nucleotide variant Likely pathogenic rs121913386 NCBI36 Chromosome 9, 21961017: 21961017
37 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
38 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
39 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
40 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
41 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
42 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
43 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
44 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
45 TP53 NM_000546.5(TP53): c.745A> T (p.Arg249Trp) single nucleotide variant Uncertain significance rs587782082 GRCh37 Chromosome 17, 7577536: 7577536
46 TP53 NM_000546.5(TP53): c.745A> T (p.Arg249Trp) single nucleotide variant Uncertain significance rs587782082 GRCh38 Chromosome 17, 7674218: 7674218
47 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
48 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 GRCh38 Chromosome 17, 7674257: 7674257
49 TP53 NM_000546.5(TP53): c.746G> A (p.Arg249Lys) single nucleotide variant Uncertain significance rs587782329 GRCh37 Chromosome 17, 7577535: 7577535
50 TP53 NM_000546.5(TP53): c.746G> A (p.Arg249Lys) single nucleotide variant Uncertain significance rs587782329 GRCh38 Chromosome 17, 7674217: 7674217

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 1662)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43751 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 33
2 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 33
3 COSM10701 TP53 skin,ear,carcinoma,squamous cell carcinoma c.824G>T p.C275F 17:7673796-7673796 33
4 COSM43544 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 33
5 COSM10656 TP53 skin,arm,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 33
6 COSM44326 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 33
7 COSM6903965 TP53 skin,ear,carcinoma,squamous cell carcinoma c.988C>T p.L330F 17:7673540-7673540 33
8 COSM45114 TP53 skin,ear,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 33
9 COSM44832 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 33
10 COSM45830 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 33
11 COSM45304 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 33
12 COSM10788 TP53 skin,ear,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 33
13 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 33
14 COSM10886 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 33
15 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 33
16 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 33
17 COSM10794 TP53 skin,ear,carcinoma,squamous cell carcinoma c.796G>A p.G266R 17:7673824-7673824 33
18 COSM43651 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 33
19 COSM43753 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 33
20 COSM43537 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 33
21 COSM10660 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 33
22 COSM44923 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>C p.A189P 17:7674966-7674966 33
23 COSM43665 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 33
24 COSM46278 TP53 skin,hand,carcinoma,squamous cell carcinoma c.950A>G p.Q317R 17:7673578-7673578 33
25 COSM45145 TP53 skin,hand,carcinoma,squamous cell carcinoma c.590T>C p.V197A 17:7674941-7674941 33
26 COSM10988 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 33
27 COSM44274 TP53 skin,hand,carcinoma,squamous cell carcinoma c.647T>A p.V216E 17:7674884-7674884 33
28 COSM45677 TP53 skin,face,carcinoma,squamous cell carcinoma c.714T>A p.C238* 17:7674249-7674249 33
29 COSM44306 TP53 skin,hand,carcinoma,squamous cell carcinoma c.845G>C p.R282P 17:7673775-7673775 33
30 COSM607136 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1247C>T p.S416F 9:99146601-99146601 33
31 COSM6962965 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 33
32 COSM6933705 RPTOR skin,ear,carcinoma,squamous cell carcinoma c.8C>A p.S3Y 17:80545637-80545637 33
33 COSM6962990 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 33
34 COSM6962984 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 33
35 COSM6962994 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 33
36 COSM6962992 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 33
37 COSM6933707 PTPRS skin,ear,carcinoma,squamous cell carcinoma c.5600A>C p.K1867T 19:5208279-5208279 33
38 COSM6962970 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 33
39 COSM456125 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 33
40 COSM1700914 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 33
41 COSM17489 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 9:95449149-95449149 33
42 COSM6962989 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 33
43 COSM6962963 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 33
44 COSM6962964 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 33
45 COSM6903910 NRAS skin,hand,carcinoma,squamous cell carcinoma c.395A>G p.E132G 1:114709624-114709624 33
46 COSM564 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 33
47 COSM585 NRAS skin,face,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 1:114713907-114713907 33
48 COSM6903909 NRAS skin,face,carcinoma,squamous cell carcinoma c.443C>T p.T148I 1:114709576-114709576 33
49 COSM574 NRAS skin,face,carcinoma,squamous cell carcinoma c.38G>T p.G13V 1:114716123-114716123 33
50 COSM1667036 NOTCH2 skin,face,carcinoma,squamous cell carcinoma c.337C>T p.R113* 1:120005407-120005407 33

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
50 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.48 BRAF HRAS TP53
2 11.36 BRAF HRAS TP53
3 11 BRAF HRAS TP53
4 9.88 HOTAIR TP53 UCA1

GO Terms for Squamous Cell Carcinoma

Sources for Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....